Patents by Inventor Kenneth J. Wilson

Kenneth J. Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10409381
    Abstract: Aspects relate to detecting gestures that relate to a desired action, wherein the detected gestures are common across users and/or devices within a surface computing environment. Inferred intentions and goals based on context, history, affordances, and objects are employed to interpret gestures. Where there is uncertainty in intention of the gestures for a single device or across multiple devices, independent or coordinated communication of uncertainty or engagement of users through signaling and/or information gathering can occur.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 10, 2019
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Meredith June Morris, Eric J. Horvitz, Andrew David Wilson, F. David Jones, Stephen E. Hodges, Kenneth P. Hinckley, David Alexander Butler, Ian M. Sands, V. Kevin Russ, Hrvoje Benko, Shawn R. LeProwse, Shahram Izadi, William Ben Kunz
  • Patent number: 10397230
    Abstract: A service processor is provided that includes a processor, a memory coupled to the processor and having instructions for executing an operating system kernel having an integrity management subsystem, secure boot firmware, and a tamper-resistant secure trusted dedicated microprocessor. The secure boot firmware performs a secure boot operation to boot the operating system kernel of the service processor. The secure boot firmware records first measurements of code executed by the secure boot firmware when performing the boot operation, in one or more registers of the tamper-resistant secure trusted dedicated microprocessor. The operating system kernel enables the integrity management subsystem. The integrity management subsystem records second measurements of software executed by the operating system kernel, in the one or more registers of the tamper-resistant secure trusted dedicated microprocessor.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 27, 2019
    Assignee: International Business Machines Corporation
    Inventors: Patrick J. Callaghan, Kenneth A. Goldman, Guerney D. H. Hunt, Elaine R. Palmer, Dimitrios Pendarakis, David R. Safford, Brian D. Valentine, George C. Wilson, Miriam Zohar
  • Patent number: 9526731
    Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: December 27, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
  • Publication number: 20160168170
    Abstract: The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A1, SEM, and W1 are as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 16, 2016
    Inventors: Jean-Pierre Andre Marc BONGARTZ, Alfred Elisabeth STAPPERS, Christopher A. TELEHA, Koen Johan Herman WEERTS, Kenneth J. WILSON
  • Patent number: 9303046
    Abstract: The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A1, SEM, and W1 are as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: April 5, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jean-Pierre André Marc Bongartz, Alfred Elisabeth Stappers, Christopher A. Teleha, Koen Johan Herman Weerts, Kenneth J. Wilson
  • Patent number: 9296726
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: March 29, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise Desjarlais, Sanath K. Meegalla, Mark Wall, Kenneth J. Wilson
  • Patent number: 9249163
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes and other disorders affected by activity of the enzyme PDE10a. Such compounds are represented by Formula (I) below, wherein R1, R2, L and Q are defined herein.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: February 2, 2016
    Assignee: JANSSEN PHARMACEUTICA NV.
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Hui Huang, Sharmila Patel, Tianbao Lu
  • Patent number: 9193736
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: November 24, 2015
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Wing S. Cheung, Hui Huang, Raymond J. Patch
  • Publication number: 20150094520
    Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Carl R. ILLIG, Shelley K. BALLENTINE, Jinsheng CHEN, Sanath K. MEEGALLA, M. Jonathan RUDOLPH, Mark J. WALL, Kenneth J. WILSON, Renee Louise DESJARLAIS, Carl M. MANTHEY, Christopher J. MOLLOY
  • Publication number: 20150051196
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
    Inventors: CARL R. ILLIG, SHELLEY K. BALLENTINE, JINSHENG CHEN, RENEE LOUISE DESJARLAIS, SANATH K. MEEGALLA, MARK WALL, KENNETH J. WILSON
  • Patent number: 8933091
    Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 13, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
  • Publication number: 20140364413
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Wing S. Cheung, Hui Huang, Raymond J. Patch
  • Publication number: 20140364414
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Applicant: JANSSEN PHARMACEUTICA, NV
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Hui Huang, Sharmila Patel, Tianbao Lu
  • Patent number: 8895584
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: November 25, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Renee Louise Desjarlais, Sanath K. Meegalla, Mark Wall, Kenneth J. Wilson
  • Publication number: 20140243382
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Carl R. ILLIG, Shelley K. Ballentine, Jinsheng Chen, Renee Louise Desjarlais, Sanath K. Meegalla, Mark Wall, Kenneth J. Wilson
  • Patent number: 8759347
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 24, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelly K. Ballentine, Jinsheng Chen, Renee Louise DesJarlais, Sanath K. Meegalla, Mark Wall, Kenneth J. Wilson
  • Patent number: 8697716
    Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: April 15, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Balltentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. DesJarlais, Carl L. Manthey, Christopher J. Molloy
  • Publication number: 20140046072
    Abstract: The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A1, SEM, and W1 are as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 13, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Jean-Pierre André Marc BONGARTZ, Alfred Elisabeth Stappers, Christopher A. Teleha, Koen Johan Herman Weerts, Kenneth J. Wilson
  • Publication number: 20140005225
    Abstract: A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee Louise Desjarlais, Carl M. Manthey, Christopher J. Molloy
  • Publication number: 20130281475
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 24, 2013
    Inventors: Carl R. Illig, Shelly K. Ballentine, Jinsheng Chen, Renee Louise, Sanath K. Meegalla, Mark Wall, Kenneth J. Wilson